azacitidin sandoz 25 mg/ml prašek za suspenzijo za injiciranje
azacitidin - prašek za suspenzijo za injiciranje - azacitidin 100 mg / 1 viala - azacitidin
azacitidine celgene
celgene europe bv - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.
azacitidine betapharm
betapharm arzneimittel gmbh - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine betapharm je indiciran za zdravljenje odraslih bolnikih, ki niso primerni za haematopoietic stem cell presaditev (hsct) z:vmesne-2 in visokim tveganjem myelodysplastic sindromov (mds) je v skladu z mednarodnim prognostic sistem točkovanja (ipss),kronične myelomonocytic levkemijo (cmml) z 10 % na 29 % mozga eksplozije brez myeloproliferative motnje,akutno mieloično levkemijo (aml) z 20 % do 30 % blastov in multi-rodbine displazija, po ocenah svetovne zdravstvene organizacije (who) razvrstitev,aml s > 30 % mozgu eksplozije glede na razvrstitev, ki.
azacitidine mylan
mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.
azacitidine accord
accord healthcare s.l.u. - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine soglasju je indicirano za zdravljenje odraslih bolnikih, ki niso primerni za haematopoietic stem cell presaditev (hsct) z:- intermediate-2 in visokim tveganjem myelodysplastic sindromov (mds) je v skladu z mednarodnim prognostic sistem točkovanja (ipss),- kronično myelomonocytic levkemijo (cmml) z 10-29 % mozga eksplozije brez myeloproliferative motnje,- akutno mieloično levkemijo (aml) z 20-30 % blastov in multi-rodbine displazija, po ocenah svetovne zdravstvene organizacije (who), in razvrščanje,- aml s >30% mozgu eksplozije glede na razvrstitev, ki.
braunol 75 mg/g dermalna raztopina
b. braun melsungen ag - povidon, jodirani - dermalna raztopina - povidon, jodirani 75 mg / 1 g - povidon-jod
braunol 75 mg/g dermalna raztopina
b. braun melsungen ag - povidon, jodirani - dermalna raztopina - povidon, jodirani 75 mg / 1 g - povidon-jod
braunol 75 mg/g dermalna raztopina
b. braun melsungen ag - povidon, jodirani - dermalna raztopina - povidon, jodirani 7,5 mg / 1 g - povidon-jod
braunol 75 mg/g dermalna raztopina
b. braun melsungen ag - povidon, jodirani - dermalna raztopina - povidon, jodirani 75 mg / 1 g - povidon-jod
vidaza
bristol-myers squibb pharma eeig - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.